TherapeuticsMD (TXMD) Stock Price, News & Analysis

Company Overview

TherapeuticsMD, Inc. (NASDAQ:TXMD) is a women's healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause. The company also markets BIJUVA, the first combination bio-identical estrogen and progesterone capsule for the treatment of moderate to severe hot flashes. In addition, TherapeuticsMD is advancing a pipeline of novel contraceptive technologies, including transdermal delivery systems and oral formulations aimed at providing more flexible dosing options.

Founded in 2015 and headquartered in Boca Raton, Florida, TherapeuticsMD has built a leadership team with extensive experience in women’s health and specialty pharmaceuticals. The organization emphasizes strategic partnerships and targeted clinical development to support product launches and lifecycle management. With a commitment to research and patient-centric care, TherapeuticsMD continues to expand its portfolio and strengthen its position in the women’s health market.

Key Stats

• Today's Range: $1.92 to $2.10
• 50-Day Range: $1.99 to $2.31
• 52-Week Range: $0.98 to $2.95
• Volume: 23,736 shs
• Average Volume: 23,009 shs
• Market Capitalization: $23.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

TherapeuticsMD Stock Analysis - MarketRank™

TherapeuticsMD scored higher than 2% of companies evaluated by MarketBeat, and ranked 854th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

TherapeuticsMD has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

TherapeuticsMD has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of TherapeuticsMD is -203.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TherapeuticsMD is -203.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TherapeuticsMD has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TXMD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TherapeuticsMD does not currently pay a dividend.

Dividend Growth

TherapeuticsMD does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added TherapeuticsMD to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TherapeuticsMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of TherapeuticsMD is held by insiders.

Percentage Held by Institutions

30.74% of the stock of TherapeuticsMD is held by institutions.

TXMD Stock Analysis - Frequently Asked Questions

How have TXMD shares performed this year?

TherapeuticsMD's stock was trading at $1.63 on January 1st, 2026. Since then, TXMD stock has increased by 24.5% and is now trading at $2.03.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) released its quarterly earnings results on Monday, March, 30th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($6.13) by $6.07. The business earned $0.89 million during the quarter, compared to analyst estimates of $19.77 million. TherapeuticsMD had a negative trailing twelve-month return on equity of 2.41% and a negative net margin of 18.83%.

When did TherapeuticsMD's stock split?

Shares of TherapeuticsMD reverse split on the morning of Monday, May 9th 2022.The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TherapeuticsMD investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 3/30/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TXMD
• Previous Symbol: NYSEMKT:TXMD
• CIK: 25743
• Web: www.therapeuticsmd.com
• Phone: (561) 961-1900
• Fax: 561-431-3389
• Employees: 420
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$570 thousand
• Net Margins: -18.83%
• Pretax Margin: -21.61%
• Return on Equity: -2.41%
• Return on Assets: -1.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.02
• Quick Ratio: 3.02

Sales & Book Value

• Annual Sales: $3.02 million
• Price / Sales: 7.78
• Cash Flow: $0.05 per share
• Price / Cash Flow: 44.37
• Book Value: $2.32 per share
• Price / Book: 0.88

Miscellaneous

• Outstanding Shares: 11,570,000
• Free Float: 11,377,000
• Market Cap: $23.49 million
• Optionable: Optionable
• Beta: 0.58